Pemafibrate
From Infogalactic: the planetary knowledge core
Jump to: navigation, search
| Clinical data | |
|---|---|
| Trade names | Parmodia |
| Routes of administration |
oral |
| Identifiers | |
| CAS Number | 848259-27-8 |
| Chemical data | |
| Molecular mass | 490.55 |
Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.
In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1mg tablets.
| GI tract |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Liver |
|
||||||||
| Blood vessels |
|
||||||||
| Combinations | |||||||||
| Other | |||||||||
|
|||||||||
|
|||||||||
Categories:
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Fibrates
